Pharmaceuticals

Endocrine-Disrupting Chemicals in Food

Volumn , Issue , 2009, Pages 459-518

  Piersma, A H ^a   Luijten, M ^a   Popov, V ^b   Tomenko, V ^b   Altstein, M ^c   Kagampang, F ^d   Schlesinger, H ^d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b WESSEX INSTITUTE OF TECHNOLOGY   (United Kingdom)

^c VOLCANI CENTER   (Israel)

^d Analyst Research Laboratories   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952240031     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781845695743.4.459     Document Type: Chapter

References (276)

1. Aherne G.W., Briggs R. The relevance of the presence of certain synthetic steroids in the aquatic environment. J Pharm Pharmacol 1989, 41:735-736.
2. Akpoviroro J.O., Mangalam M., Jenkins N., Fotherby K. Binding of the contraceptive steroids medroxyprogesterone acetate and ethynyloestradiol in blood of various species. J. Steroid Biochem. 1981, 14:493-498.
3. Alleva J.J., Alleva F.R. Synergistic inhibition by benzodiazepine and barbiturate drugs of the clock control of ovulation in hamsters. Chronobiol. Int. 1995, 12:1-7.
4. Andersen O.P., Hansen P., Madsen H. Hyperprolactinemic amenorrhea induced by metoclopamid (PrimperanR). Acta Obstet. Gynecol. Scand. 1981, 60:341-342.
5. Andreozzi R., Raffaele M., Nicklas P. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 2003, 50:1319-1330.
6. Archand-Hoy L.D., Nimrod A.C., Benson W.H. Endocrine-modulating substances in the environment: estrogenic effects of pharmaceutical products. Int. J. Toxicol. 1998, 17:139-158.
7. Armstrong D.T., Grinwich D.L. Blockade of spontaneous and LH-induced ovulation in rats by indomethacin, an inhibitor of prostaglandin biosynthesis. I. Prostaglandins 1972, 1:21-28.
8. Arze R.S., Ramos J.M., Rashid H.U., Kerr D.N. Amenorrhoea, galactorrhoea, and hyperprolactinaemia induced by methyldopa. Br. Med. J. (Clin. Res. Ed.) 1981, 283:194.
9. Ashby J., Lefevre P.A., Odum J., Tinwell H., Kennedy S.J., Beresford N., Sumpter J.P. Failure to confirm estrogenic activity for benzoic acid and clofibrate: implications for lists of endocrine-disrupting agents. Regul. Toxicol. Pharmacol. 1997, 26:96-101.
10. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci. Total. Environ. 2004, 333:167-184.
11. Asikainen A., Kolehmainen M., Ruuskanen J., Tuppurainen K. Structure-based classification of active and inactive estrogenic compounds by decision tree, LVQ and kNN methods. Chemosphere 2006, 62(4):658-673.
12. Back D.J., Breckenridge A.M., Crawford F.E., et al. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin. Pharmacol. Ther. 1978, 24:448-453.
13. Back D.J., Bates M., Breckenridge J.M., et al. The pharmacokinetics of levonorgestrel and ethinylestradiol in women - studies with Ovran and Ovranette. Contraception 1981, 23:229-239.
14. Bain S.C., Lemon M., Jones A.F. Gemfibrozil-induced impotence. Lancet 1990, 336:1389.
15. Baird D.T. Endocrinology of female infertility. Br. Med. Bull. 1979, 35:193-198.
16. Bancroft J., Tennent G., Loucas K., Cass J. The control of deviant sexual behaviour by drugs. I. Behavioural changes following oestrogens and anti-androgens. Br. J. Psychiatry 1974, 125:310-315.
17. Barnes T.R., Bamber R.W., Watson J.P. Psychotropic drugs and sexual behaviour. Br. J. Hosp. Med. 1979, 21:594-600.
18. Bathen J. Propranolol erectile dysfunction relieved. Ann. Intern. Med. 1978, 88:716-717.
19. bbc Prozac 'found in drinking water 2004, http://www.news.bbc.co.uk/1/hi/health/3545684.stm.
20. Beardmore K.S., Morris J.M., Gallery E.D. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens. Pregnancy 2002, 21:85-95.
21. Bebb R.A., Anawalt B.D., Christensen R.B., Paulsen C.A., Bremner W.J., Matsumoto A.M. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol. Metab. 1996, 81(2):757-762.
22. Beeley L. Drug-induced sexual dysfunction and infertility. Adverse Drug React Acute Poisoning Rev. 1984, 3:23-42.
23. Belfroid A.C., Van Der Horst A., Vethaak A.D., SchÄFer A.J., Rijs G.B., Wegener J., Cofino W.P. Analysis and occurrence of estrogenic hormones and their glucuronides in surface water and waste water in The Netherlands. Sci. Total Environ. 1999, 225(1-2):101-108.
24. Ben Rafael Z., Mastroianni L., Meloni F., Lee M.S., Flickinger G.L. Total estradiol, free estradiol, sex hormone-binding globulin, and the fraction of estradiol bound to sex hormone-binding globulin in human follicular fluid. J. Clin. Endocrinol. Metab. 1986, 63:1106-1111.
25. Bendz D., Paxeus N.A., Ginn T.R., Loge F.J. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Hoje River in Sweden. J. Hazard. Mater. 2005, 122:195-204.
26. Berg C., Halldin K., Fridolfsson A.-K., Brandt I., Brunstro B. The avian egg as a test system for endocrine disrupters: effects of diethylstilbestrol and ethynylestradiol on sex organ development. The Science of the Total Environment 1999, 233:57-66.
27. Biron P. Diminished libido with cimetidine therapy. Can. Med. Assoc. J. 1979, 121:404-405.
28. Blagg N.A., Gleckman R.A. Erythromycin. new indications and toxicities. Postgrad. Med. 1981, 69(3):59-68.
29. Boyd A.S. Varicoceles and male infertility. Am. Fam. Physician 1988, 37:252-258.
30. Boxall A.B. The environmental side effects of medication. EMBO Rep. 2004, 5:1110-1116.
31. Brooks B.W., Chambliss C.K., Stanley J.K., Ramirez A., Banks K.E., Johnson R.D., Lewis R.J. Determination of select antidepressants in fish from an effluent-dominated stream. Environ. Toxicol. Chem. 2005, 24:464-469.
32. Buvat J. Androgen therapy with dehydroepiandrosterone. World J. Urol. 2003, 21:346-355.
33. Cameron S.T., Critchley H.O., Thong K.J., Buckley C.H., Williams A.R., Baird D.T. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum. Reprod. 1996, 11:2518-2526.
34. Cargouet M., Perdiz D., Mouatassim-Souali A., Tamisier-Karolak S., Levi Y. Assessment of river contamination by estrogenic compounds in Paris area (France). Science of the Total Environment 2004, 324:55-66.
35. Carp H.J., Fein A., Nebel L. Effect of diclofenac on implantation and embryonic development in the rat. Eur. J. Obstet. Gynecol. Reprod. Biol. 1988, 28:273-277.
36. Cavalier M. Sexually speaking ... the dance. Alaska Med. 1995, 37:113.
37. Chandra D., Thulasimany M., Biswas A.R. Uterotropic effect of clofibrate and phenylbutazone in immature female rats. Indian J. Physiol. Pharmacol. 1982, 26:147-151.
38. Chang S.W., Fine R., Siegel D., Chesney M., Black D., Hulley S.B. The impact of diuretic therapy on reported sexual function. Arch. Intern. Med. 1991, 151:2402-2408.
39. Chowdhury A.R. Effect of pharmacological agents on male reproduction. Adv. Contracept. Deliv. Syst. 1987, 3:347-352.
40. Clayton D.O., Shen W.W. Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management. Drug Saf. 1998, 19:299-312.
41. Cohen A.J., Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J. Sex Marital Ther. 1998, 24:139-143.
42. Colucci M.S., Topp E. Persistence of estrogenic hormones in agricultural soils: II. 17a-Ethynylestradiol. J. Environ. Qual. 2001, 30:2077-2080.
43. Compton M.T., Miller A.H. Priapism associated with conventional and atypical antipsychotic medications: a review. J. Clin. Psychiatry 2001, 62:362-366.
44. Cortes A., Merino G., Contreras E. Effect of fluoxetine (Lilly II0I40) on serotonin, noradrenaline and acetylcholine in isolated organs. Cell. Mol. Biol. Incl. Cyto. Enzymol. 1978, 23:179-182.
45. Corton J.C., Bocos C., Moreno E.S., Merritt A., Cattley R.C., Gustafsson J.A. Peroxisome proliferators alter the expression of estrogen-metabolizing enzymes. Biochimie 1997, 79:151-162.
46. Cox D.R., Lindley D.V. Theoretical Statistics 1974, Chapman &Hall, London.
47. Cramer D.W., Liberman R.F., Hornstein M.D., Mcshane P., Powers D., Li E.Y., Barbieri R. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil. Steril. 1998, 70:371-373.
48. Crotty K.L., May R., Kulvicki A., Kumar D., Neal D.E. The effect of antimicrobial therapy on testicular aspirate flow cytometry. J. Urol. 1995, 153:835-838.
49. Crump K. A new method for determining allowable daily intakes. Fundamental Appl. Toxicol. 1984, 4:854-871.
50. Crump K., Allen B., Faustman E. The Use of Benchmark Dose Approach in Health Risk Assessment 1995, EPA/630/R-94/007.
51. Cutler G.B., Sauer M.A., Loriaux D.L. SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone. J. Pharmacol Exp. Ther. 1979, 209:144-146.
52. Dail W.G., Mcguffee L., Minorsky N., Little S. Responses of smooth muscle strips from penile erectile tissue to drugs and transmural nerve stimulation. J. Auton. Pharmacol. 1987, 7:287-293.
53. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products in the environment: agents of subtle change?. Environ. Health Perspect. 1999, 107(6):907-938.
54. Davies T.S., Klowe W.M. Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem Toxicol. 1998, 21(4):521-537.
55. De Groot AC De, Eshuis H., Stricker B.H. In effectiviteit van orale anticonceptic tijdens gebruik van minocycline (in Dutch). Ned Tijdschr Geneeskd. 1990, 134(25):1227-1229.
56. Della C.A., Pfiffner D., Meier B., Hess O.M. Sexual activity in hypertensive men. J. Hum. Hypertens. 2003, 17:515-521.
57. Desbrow C., Routledge E.J., Brighty G.C., Sumpter J.P., Waldock M. Identification ofestrogenic chemicals in STW effluent. 1. Chemical fractionation andin vitro biological screening. Environ. Sci. Technol. 1998, 32(11):1549-1558.
58. Dmowski W.P. Danazol-induced pseudomenopause in the management of endometriosis. Clin. Obstet. Gynecol. 1988, 31:829-839.
59. Dorevitch A., Davis H. Fluvoxamine-associated sexual dysfunction. Ann. Pharmacother. 1994, 28:872-874.
60. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005, 65:773-786.
61. El Banna A.A., Al Gahtani S.J., Sedrani S.H. Effect of indomethacin administered during the normal time of implantation on the progesterone and protein composition of plasma and uterine flushings of rabbits. J. Reprod. Fertil. 1993, 97:277-285.
62. El Etreby M.F., Neumann F. Hormones and Cancer. Influence of sex steroids and steroid antagonists on hormone-dependent tumors in experimental animals 1980, 321-336. Raven Press, New York. S. Iacobelli, R.J.B. King, H.R. Lindner, M.E. Lippman (Eds.).
63. El Sayed M.G., El Sayed M.T., Elazab Abd E.S., Hafeiz M.H., El Komy A.A., Hassan E. Effects of some beta-adrenergic blockers on male fertility parameters in rats. Dtsch. Tierarztl. Wochenschr. 1998, 105:10-12.
64. Environmental Protection Agency ) Reference Dose (RfD): Description and Use in Health Risk Assessments 1993, US EPA. http://www.epa.gov/iris/rfd.htm.
65. Espey L.L. Comparison of the effect of nonsteroidal and steroidal antiinflammatory agents on prostaglandin production during ovulation in the rabbit. Prostaglandins 1983, 26:71-78.
66. Espey L.L., Stein V.I., Dumitrescu J. Survey of antiinflammatory agents and related drugs as inhibitors of ovulation in the rabbit. Fertil. Steril. 1982, 38:238-247.
67. European Chemicals Bureau European Commission Technical Guidance Document in Support of Commission Directive 93/67/EEC on Risk Assessment for New Notified Substances and Commission Regulation No. 1488/94 on Risk Assessment for Existing Substances 2003, Office for Official Publications of the European Communities, Luxembourg, 1996 (and as revised, 2003).
68. Falkson C.I., Falkson G., Falkson H.C. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin. Ann. Oncol. 1991, 2:303-304.
69. Fell M.J., Marshall K.M., Williams J., Neill J.C. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J. Psychopharmacol. 2004, 18:149-155.
70. Fell M.J., Gibson R., Mcdermott E., Sisodia G., Marshall K.M., Neill J.C. Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav. Brain Res. 2005, 160:338-343.
71. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquatic Toxicol. 2006, 76:122-159.
72. Ferrari B., Paxeus N., Lo G.R., Pollio A., Garric J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol. Environ. Saf. 2003, 55:359-370.
73. Fernandez P.R., Kessler A.G., Rawlins R.G. Modern approaches to the treatment of human infertility through assisted reproduction. P. R. Health Sci. J. 1991, 10:75-81.
74. Ficicioglu C., Tekin H.I., Arioglu P.F., Okar I. A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats. Acta Eur. Fertil. 1995, 26:75-79.
75. Fitzgerald J.E., Petrere J.A., De La Iglesia F.A. Experimental studies on reproduction with the lipid-regulating agent gemfibrozil. Fundam. Appl. Toxicol. 1987, 8:454-464.
76. Fogari R., Preti P., Derosa G., Marasi G., Zoppi A., Rinaldi A., Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur. J. Clin. Pharmacol. 2002, 58:177-180.
77. Fotherby K., Caldwell A.D.S. New progestogens in oral contraception. Contraception 1994, 49:1-31.
78. Frances A., Kaplan H.S. Patient on hypertensive drug has increasing erectile problems. Hosp. Community Psychiatry 1982, 33:431-432.
79. Fraunfelder F.T., Meyer S.M. Sexual dysfunction secondary to topical ophthalmic timolol. JAMA 1985, 253:3092-3093.
80. Fovaeus M., Andersson K.E., Hedlund H. Effects of some calcium channel blockers on isolated human penile erectile tissues. J. Urol. 1987, 138:1267-1272.
81. Furuhjelm M., Rydner T., Carlstrom K. Hyperprolactinemia in cases of infertility and amenorrhea. Acta. Obstet. Gynecol. Scand. 1980, 59:137-141.
82. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. 2005, 28:137-152.
83. Giuliano F., Allard J. Dopamine and sexual function. Int. J. Impot. Res. 2001, 13(3):S18-S28.
84. Gnoth C., Godehardt E., Frank-Herrmann P., Friol K., Tigges J., Freundl G. Definition and prevalence of subfertility and infertility. Hum. Reprod. 2005, 20:1144-1147.
85. Godo G. Hyperprolactinaemia and female infertility. Acta. Med. Hung. 1984, 41:185-193.
86. Gonzalez-Villapando C., Szabo M., Frohman L.A. Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 1980, 51:1417-1424.
87. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., Khan Z.M. Antidepressant-induced sexual dysfunction. Ann. Pharmacother. 2002, 36:1577-1589.
88. Gross B., Montgomery-Brown J., Naumann A., Reinhard M. Occurrence and fate of pharmaceuticals and alkylphenol ethoxylate metabolites in an effluent-dominated river and wetland. Environ. Toxicol. Chem. 2004, 23:2074-2083.
89. Gupta S., Masand P., Ashton A.K., Berry S.L. Phenelzine-induced sexual dysfunction treated with sildenafil. J. Sex Marital Ther. 1999, 25:131-135.
90. Gutendorf B., Westendorf J. Comparison of an array ofin vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology 2001, 166:79-89.
91. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
92. Hafez E.S., Hafez S.D. Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. Arch. Androl. 2005, 51:15-31.
93. Hahlbeck E., Katsiadaki I., Mayer I., Adolfsson-Erici M., James J., Bengtsson B.E. The juvenile three-spined stickleback (Gasterosteus aculeatus L.) as a model organism for endocrine disruption II-kidney hypertrophy, vitellogenin and spiggin induction. Aquat. Toxicol. 2004, 70(4):311-326.
94. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36:357-393.
95. Hargreaves C.A., Rogers S., Hills F., Rahman F., Howell R.J., Homa S.T. Effects of co-trimoxazole, erythromycin, amoxycillin, tetracycline and chloroquine on sperm functionin vitro. Hum. Reprod. 1998, 13:1878-1886.
96. Harries J.E., Sheahan D.A., Jobling S., Matthiessen P., Neall P., Routledge E.J., Rycroft R., Sumpter J.P., Tylor T. A survey of estrogenic activity in United Kingdom inland water. Environ. Toxicol. Chem. 1996, 15:1993-2002.
97. Harries J.E., Sheahan D.A., Jobling S., Matthiessen P., Neall P., Sumpter J.P., Tylor T., Zaman N. Estrogenic activity in five United Kingdom rivers detected by vitellogenesis in caged male trout. Environ. Toxicol. Chem. 1997, 16:534-542.
98. Hashimoto F., Oguchi Y., Morita M., Matsuoka K., Takeda S., Kimura M., Hayashi H. PPARalpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. Biochem. Pharmacol. 2004, 68:313-321.
99. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol. Lett. 2002, 131:5-17.
100. Hedlund H., Andersson K.E. Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J. Auton. Pharmacol. 1985, 5:81-88.
101. Hedlund H., Andersson K.E. Effects of prazosin in men with symptoms of bladder neck obstruction and a non-hyperplastic prostate. Scand. J. Urol. Nephrol. 1989, 23:251-254.
102. Heikkine T., Ekblad U., Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. Brit. J. Obst. Gynecol. 2002, 109:1003-1008.
103. Helm F., Kretzschmar R., Leuschner F., Neumann W. Investigations on the effect of the combination sulfamoxole/trimethoprim on fertility and fetal development in rats and rabbits (author's tranls)]. Arzneimittelforschung. 1976, 26:643-651.
104. Hendrick V., Stowe Z.N., Altshuler L.L., Hwang S., Lee E., Haynes D. Placental passage of antidepressant medications. Am. J. Psychiatry 2003, 160:993-996.
105. Hirsch R., Ternes T., Haberer K., Kratz K.L. Occurrence of antibiotics in the aquatic environment. Sci. Total Environ. 1999, 225:109-118.
106. Hohenblum P., Gans O., Moche W., Scharf S., Lorbeer G. Monitoring of selected estrogenic hormones and industrial chemicals in groundwaters and surface waters in Austria. Sci. Total Environ. 2004, 333:185-193.
107. Holmes B., Sorkin E.M. Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases. Drugs 1986, 31:467-499.
108. Holzbeierlein J.M., Castle E.P., Thrasher J.B. Complications of androgen-deprivation therapy for prostate cancer. Clin. Prostate Cancer 2003, 2:147-152.
109. Holzbeierlein J.M., Mclaughlin M.D., Thrasher J.B. Complications of androgen deprivation therapy for prostate cancer. Curr. Opin. Urol. 2004, 14:177-183.
110. Hu X.H., Bull S.A., Hunkeler E.M., Ming E., Lee J.Y., Fireman B., Markson L.E. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J. Clin. Psychiatry 2004, 65:959-965.
111. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberbauer H., Fleischhacker W.W. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am. J. Psychiatry 1999, 156:631-633.
112. IARC Monographs 1979, 21:233-255. 257-278, 387-395.
113. IARC Monographs 1979, 21:441-460.
114. IARC Monographs 1987, 6:427-429.
115. Isojarvi J.I., Lofgren E., Juntunen K.S., Pakarinen A.J., Paivansalo M., Rautakorpi I., Tuomivaara L. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 2004, 62:247-253.
116. Isojarvi J.I., Tauboll E., Herzog A.G. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005, 19:207-223.
117. Johnson D.J., Sanderson H., Brain R.A., Wilson C.J., Bestari K.J., Solomon K.R. Exposure assessment and microcosm fate of selected selective serotonin reuptake inhibitors. Regul. Toxicol. Pharmacol. 2005, 42:313-323.
118. Jorgensen H., Knigge U., Kjaer A., Warberg J. Interactions of histaminergic and serotonergic neurons in the hypothalamic regulation of prolactin and ACTH secretion. Neuroendocrinology 1996, 64:329-336.
119. Joseph J.C., Schuna A.A. Management of hypertension in the diabetic patient. Clin. Pharm. 1990, 9:864-873.
120. Juchem M., Pollow K., Elger W., Hoffmann G., Möbus V. Receptor binding of norgestimate - a new orally active synthetic progestational compound. Contraception 1993, 47:283-294.
121. Judd S.J., Lazarus L., Compton P. Hyperprolactinaemia: its physiology and investigation. Med. J. Aust. 1976, 2:23-25.
122. Jurgens M.D., Holthaus K.I.E., Johnson A.C., Smith J.J.L., Hetheridge M., Williams R.J. The potential for estradiol and ethinylestradiol degradation in English rivers. Environ. Toxicol. Chem. 2002, 21(3):480-488.
123. Khan U.A., Aslam M., Saeed S.A. Effect of beta adrenergic antagonist on the production of testosterone by rat's Leydig cells. J. Ayub. Med. Coll. Abbottabad. 2004, 16:26-28.
124. Kallen B.A.J., Olausson P.O. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod. Toxicol. 2003, 17:255-261.
125. Kallen B.A.J., Olausson P.O., Danielsson B.R. Is erythromycin teratogenic in humans?. Reprod. Toxicol. 2005, 20:209-214.
126. Kanaly K.A., Berman J.R. Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction. Curr. Womens Health Rep. 2002, 2:409-416.
127. Katz I.M. Sexual dysfunction and ocular timolol. JAMA 1986, 255:37-38.
128. Karthikeyan K.G., Meyer M.T. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci. Total Environ. 2006, 361(1-3):196-207.
129. Keene L.C., Davies P.H. Drug-related erectile dysfunction. Adverse Drug React. Toxicol. Rev. 1999, 18:5-24.
130. Kelly D.L., Conley R.R. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006, 31(3):340-346.
131. Kher R., Kalla N.R. Antifertility effects of an LHRH agonist in male mice. Contraception 1996, 53:299-306.
132. Killick S., Elstein M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil. Steril. 1987, 47:773-777.
133. King K., Chan P.J., Patton W.C., King A. Antibiotics: effect on cryopreserved-thawed human sperm motilityin vitro. Fertil. Steril. 1997, 67(6):1146-1151.
134. Klein T.A., Richmond J.A., Mishell D.R. Pelvic tuberculosis. Obstet. Gynecol. 1976, 48:99-104.
135. Kloner R.A. Erectile dysfunction in the cardiac patient. Curr. Urol. Rep. 2003, 4:466-471.
136. Knobil E. The neuroendocrine control of ovulation. Hum. Reprod. 1988, 3:469-472.
137. Knobil E. The hypothalamic gonadotrophic hormone releasing hormone (GnRH) pulse generator in the rhesus monkey and its neuroendocrine control. Hum. Reprod. 1988, 3:29-31.
138. Knobil E. The GnRH pulse generator. Am. J. Obstet. Gynecol. 1990, 163:1721-1727.
139. Kolettis P.N. Evaluation of the subfertile man. Am. Fam. Physician 2003, 67:2165-2172.
140. Korner W., Spengler P., Bolz U., Schuller W., Hanf V., Metzger J.W. Substances with estrogenic activity in effluents of sewage treatment plants in southwestern Germany. 2. Biological analysis. Environ. Chem. Toxicol. 2001, 20:2142.
141. Kroes R., Muller D., Lambe J., Loewik M.R.H., Van Klaveren J., Kleiner J., Massey R., Mayer S., Urieta I., Verger P., Visconti A. Assessment of intake from the diet. Food Chem. Toxicol. 2002, 40:327-385.
142. Kushniruk I.I. Effect of several antibacterial preparations on the concentration of nucleic acids in spermatogenic epithelial cells]. Tsitol. Genet. 1976, 10:342-344.
143. Kuch H.M., Ballschmiter K. Determination of endogenous and exogenous estrogens in effluents from sewage treatment plants at the ng/L-level. Fresenius J. Anal. Chem. 2000, 366:392-395.
144. Kuhnz W., Heuner A., Humpel M., Seifert W., Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception 1997, 56:379-385.
145. Labbate L.A., Croft H.A., Oleshansky M.A. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J. Clin. Psychiatry 2003, 64(10):11-19.
146. Lam M.W., Young C.J., Brain R.A., Johnson D.J., Hanson M.A., Wilson C.J., Richards S.M., Solomon K.R., Mabury S.A. Aquatic persistence of eight pharmaceuticals in a microcosm study. Environ. Toxicol. Chem. 2004, 23:1431-1440.
147. Länge R., Hutchinson T.H., Croudace C.P., Siegmund F., Schweinfurth H., Hampe P., Panter G.H., Sumpter J.P. Effects of the synthetic estrogen 17-ethinylestradiol on the life-cycle of the fathead minnow (Pimephales promelas). Environ. Toxicol. Chem. 2001, 20:1216-1227.
148. Larsson D.G.J., Adolfsson-Erici M., Parkkonen J., Pettersson M., Berg A.H., Olsson P.-E., Forlin L. Ethinyloestradiol - an undesired fish contraceptive?. Aquatic Toxicol. 1999, 45:91-97.
149. Lesko L.M., Stotland N.L., Segraves R.T. Three cases of female anorgasmia associated with MAOIs. Am. J. Psychiatry 1982, 139:1353-1354.
150. Lindberg R.H., Wennberg P., Johansson M.I., Tysklind M., Andersson B.A. Screening of human antibiotic substances and determination of weekly mass flows in five sewage treatment plants in Sweden. Environ. Sci. Technol. 2005, 39:3421-3429.
151. Lindqvist N., Tuhkanen T., Kronberg L. Occurrence of acidic pharmaceuticals in raw and treated sewages and in receiving waters. Water Res. 2005, 39:2219-2228.
152. Liu R.C., Hahn C., Hurtt M.E. The direct effect of hepatic peroxisome proliferators on rat Leydig cell functionin vitro. Fundam. Appl. Toxicol. 1996, 30:102-108.
153. Luijten M., Tomenko V., Popov V., Piersma A.H. A scenariospecific prioritization list of chemicals bearing a high potential of affecting human fecundity 2005, D1.1. Contract No. FOOD-CT-2004-513953.
154. Mantero F., Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann. Endocrinol (Paris) 2000, 61:52-60.
155. Marik J., Hulka J. Luteinized unruptured follicle syndrome: a subtle cause of infertility. Fertil. Steril. 1978, 29:270-274.
156. Marti B. Health effects of recreational running in women. Some epidemiological and preventive aspects. Sports Med. 1991, 11:20-51.
157. Masala A., Delitala G., Devilla L., Alagna S., Rovasio P.P. Enhancement of insulin-induced prolactin secretion by fluoxetine in man. J. Clin. Endocrinol. Metab. 1979, 49:350-352.
158. Matuszkiewicz-Rowinska J., Skorzewska K., Radowicki S., Sokalski A., Przedlacki J., Niemczyk S., Wlodarczyk D., Puka J., Switalski M. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol. Dial. Transplant 1999, 14:1238-1243.
159. Melman A., Fersel J., Weinstein P. Further studies on the effect of chronic alpha-methyldopa administration upon the central nervous system and sexual function in male rats. J. Urol. 1984, 132:804-808.
160. Meltzer H.Y., Fang V.S., Tricou B.J., Robertson A. Effect of antidepressants on neuroendocrine axis in humans. Adv. Biochem Psychopharmacol. 1982, 32:303-316.
161. Meston C.M. A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction. J. Sex Marital Ther. 2004, 30:57-68.
162. Meston C.M., Gorzalka B.B., Wright J.M. Inhibition of subjective and physiological sexual arousal in women by clonidine. Psychosom. Med. 1997, 59:399-407.
163. Metcalfe C.D., Metcalfe T.L., Kiparissis Y., Koenig B.G., Khan C., Hughes R.J., Croley T.R., Raymond E.M., Potter T. Estrogenic potency of chemicals detected in sewage treatment plant effluents as determined byin vivo assays with Japanese medaka (Oryzias latipes). Environ. Toxicol. Chem. 2001, 20:297-308.
164. Metcalfe C.D., Miao X.S., Koenig B.G., Struger J. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environ. Toxicol. Chem. 2003, 22:2881-2889.
165. Miao X.S., Metcalfe C.D. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Anal. Chem. 2003, 75:3731-3738.
166. Miao X.S., Bishay F., Chen M., Metcalfe C.D. Occurrence of antimicrobials in the final effluents of wastewater treatment plants in Canada. Environ. Sci. Technol. 2004, 38:3533-3541.
167. Mikkonen K., Tapanainen P., Pakarinen A.J., Paivansalo M., Isojarvi J.I., Vainionpaa L.K. Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 2004, 45:769-776.
168. Mimeault C., Woodhouse A.J., Miao X.S., Metcalfe C.D., Moon T.W., Trudeau V.L. The human lipid regulator, gemfibrozil bioconcentrates and reduces testosterone in the goldfish,Carassius auratus. Aquat. Toxicol. 2005, 73:44-54.
169. Mitch R.A. Carbamazepine toxicity precipitated by intravenous erythromycin. DICP 1989, 23(11):878-879.
170. Molitch M.E. Pathologic hyperprolactinemia. Endocrinol. Metab. Clin. North Am. 1992, 21:877-901.
171. Montejo-Gonzalez A.L., Llorca G., Izquierdo J.A., Ledesma A., Bousono M., Calcedo A., Carrasco J.L., Ciudad J., Daniel E., De La G.J., Derecho J., Franco M., Gomez M.J., Macias J.A., Martin T., Perez V., Sanchez J.M., Sanchez S., Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. 1997, 23:176-194.
172. Montgomery S.A., Baldwin D.S., Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J. Affect. Disord. 2002, 69:119-140.
173. Morrissette D.L., Skinner M.H., Hoffman B.B., Levine R.E., Davidson J.M. Effects of antihypertensive drugs atenolol and nifedipine on sexual function in older men: a placebo-controlled, crossover study. Arch. Sex Behav. 1993, 22:99-109.
174. Morrison J.L., Riggs K.W., Rurak D.W. Fluoxetine during pregnancy: impact on fetal development. Reprod. Fertil. Dev. 2005, 17:641-650.
175. Moss H.B. More cases of anorgasmia after MAOI treatment. Am. J. Psychiatry 1983, 140:266.
176. Moss H.B., Procci W.R. Sexual dysfunction associated with oral antihypertensive medication: a critical survey of the literature. Gen. Hosp. Psychiatry 1982, 4:121-129.
177. Muller S.C., El Damanhoury H., Ruth J., Lue T.F. Hypertension and impotence. Eur. Urol. 1991, 19:29-34.
178. Murdia A., Mathur V., Kothari L.K., Singh K.P. Sulpha-trimethoprim combinations and male fertility. Lancet 1978, 2:375-376.
179. Nafziger A.N., Bertino J.S., Goss-Bley A.I., Kashuba A.D. Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. J. Clin. Psychiatry 1999, 60:187-190.
180. Nash J.P., Kime D.E., Van Der Ven L.T., Wester P.W., Brion F., Maack G., Stahlschmidt-Allner P., Tyler C.R. Long-term exposure to environmental concentrations of the pharmaceutical ethynylestradiol causes reproductive failure in fish. Environ. Health Perspect. 2004, 112(17):1725-1733.
181. Newman R.J., Salerno H.R. Letter: Sexual dysfunction due to methyldopa. Br. Med. J. 1974, 4:106.
182. Nulman I., Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996, 53:304-308.
183. Oehninger S., Alexander N.J. Male infertility: the focus shifts to sperm manipulation. Curr. Opin. Obstet. Gynecol. 1991, 3:182-190.
184. O'Grady J.P., Caldwell B.V., Auletta F.J., Speroff L. The effects of an inhibitor of prostaglandin synthesis (indomethacin) on ovulation, pregnancy, and pseudopregnancy in the rabbit. Prostaglandins 1972, 1:97-106.
185. Olive D.L., Lindheim S.R., Pritts E.A. Endometriosis and infertility: what do we do for each stage?. Curr. Womens Health Rep. 2003, 3:389-394.
186. Orme M.L.E., Back D.J., Breckenbridge A.M. Clinical pharmacokinetics of oral contraceptives. Clin. Pharmacokinetics 1983, 8:95-136.
187. Orme M., Back D.J., Ward S., et al. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception 1991, 43:305-316.
188. Orn S., Holbech H., Madsen T.H., Norrgren L., Petersen G.I. Gonad development and vitellogenin production in zebrafish (Danio rerio) exposed to ethinylestradiol and methyltestosterone. Aquat. Toxicol. 2003, 65(4):397-411.
189. Ou Y.C., Hwang T.I., Yang C.R., Chang C.L., Chang C.H., Wu H.C., Hwang Y.F. Hormonal screening in impotent patients. J. Formos. Med. Assoc. 1991, 90:560-564.
190. Pall M., Friden B.E., Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum. Reprod. 2001, 16:1323-1328.
191. Papoulias D.M., Noltie D.B., Tillitt D.E. Anin vivo model fish system to test chemical effects on sexual differentiation and development: exposure to ethinyl estradiol. Aquatic Toxicol. 1999, 48:37-50.
192. Patel R., Rosengren R.J. Acetaminophen elicits anti-estrogenic but not estrogenic responses in the immature mouse. Toxicol. Lett. 2001, 122:89-96.
193. Pentland B., Anderson D.A., Critchley J.A. Failure of ejaculation with indoramin. Br. Med. J. (Clin. Res. Ed.) 1981, 282:1433-1434.
194. Peterson E.W., Davis R.K., Orndorff H.A. 17-Estradiol as an indicator of animal waste contamination in mantled karst aquifers. J. Environ. Qual. 2001, 29:826-834.
195. Pierce J.R. Cimetidine-associated depression and loss of libido in a woman. Am. J. Med. Sci. 1983, 286:31-34.
196. Pizarro S., Bargay J., D'Agosto P. Gemfibrozil-induced impotence. Lancet 1990, 336:1135.
197. Pohl R. Anorgasmia caused by MAOIs. Am. J. Psychiatry 1983, 140:510.
198. Pohland R.C., Byrd T.K., Hamilton M., Koons J.R. Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol. Appl. Pharmacol. 1989, 98:198-205.
199. Prescott L.F. Paracetamol: past, present, and future. Am. J. Ther. 2000, 7:143-147.
200. Purdom C.E., Hardiman P.A., Bye V.J., Eno N.C., Tyler C.R., Sumpter J. Estrogenic effects of effluents from sewage treatment works. Chem. Ecol. 1994, 8:275-285.
201. Ranney R.E. Comparative metabolism of 17-ethynyl steroids used in oral contraceptives. J. Toxicol. Environ. Health 1977, 3:139-166.
202. Rathner M Von, Sonneborn M. Biologishe wirksame Oestrogene in Trink- und Abwasser. Forum Staedte. Hygiene 1979, 30:45-49.
203. Reel J.R., Lawton A.D., Lamb J.C. Reproductive toxicity evaluation of acetaminophen in Swiss CD-1 mice using a continuous breeding protocol. Fundam. Appl. Toxicol. 1992, 18:233-239.
204. Richardson M.L., Bowron J.M. The fate of pharmaceutical chemicals in the aquatic environment. J. Pharm. Pharmacol. 1985, 37:1-12.
205. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci. Total Environ. 2006, 356(1-3):143-153.
206. Robinson C.D., Brown E., Craft J.A., Davies I.M., Moffat C.F., Pirie D., Robertson F., Stagg R.M., Struthers S. Effects of sewage effluent and ethynyl oestradiol upon molecular markers of oestrogenic exposure, maturation and reproductive success in the sand goby (Pomatoschistus minutus, Pallas). Aquatic Toxicol. 2003, 62:119-134.
207. Rosen R.C., Marin H. Prevalence of antidepressant-associated erectile dysfunction. J. Clin. Psychiatry 2003, 64(10):5-10.
208. Rosen R.C., Kostis J.B., Jekelis A.W. Beta-blocker effects on sexual function in normal males. Arch. Sex Behav. 1988, 17:241-255.
209. Rosen R.C., Lane R.M., Menza M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol 1999, 19:67-85.
210. Rossi A.G., Soares J.M., Motta E.L., Simoes M.J., Oliveira-Filho R.M., Haidar M.A., Rodrigues D.L., Baracat E.C. Metoclopramide-induced hyperprolactinemia affects mouse endometrial morphology. Gynecol. Obstet. Invest. 2002, 54:185-190.
211. Roste L.S., Tauboll E., Haugen T.B., Bjornenak T., Saetre E.R., Gjerstad L. Alterations in semen parameters in men with epilepsy treated with valproate or carbamazepine monotherapy. Eur. J. Neurol. 2003, 10:501-506.
212. Rudkin L., Taylor M.J., Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst. Rev. 2004, CD003382.
213. Schardein J.L. Studies on the components of an oral contraceptive agent in albino rats. II. Progestogenic component and comparison of effects of the components and the combined agent. J. Toxicol. Environ. Health 1980, 6:895-906.
214. Schlegel P.N., Chang T.S., Marshall F.F. Antibiotics: potential hazards to male fertility. Fertil. Steril. 1991, 55(2):235-242.
215. Scholz S., Gutzeit H.O. 17-a-ethinylestradiol affects reproduction, sexual differentiation and aromatase gene expression of the medaka (Oryzias latipes). Aquatic Toxicol. 2000, 50:363-373.
216. Segraves R.T. Sexual side-effects of psychiatric drugs.Int. J. Psychiatry Med. 1988, 18:243-252.
217. Shen W.W., Mallya A.R. MAOI-induced inhibited female orgasm. Am. J. Psychiatry 1983, 140:1275.
218. Shen W.W., Park S. Thioridazine-induced inhibition of female orgasm. Psychiatr. J. Univ. Ott. 1982, 7:249-251.
219. Shen W.W., Sata L.S. Inhibited female orgasm resulting from psychotropic drugs. A clinical review. J. Reprod. Med. 1983, 28:497-499.
220. Shen W.W., Sata L.S. Inhibited female orgasm resulting from psychotropic drugs. A five-year, updated, clinical review. J. Reprod. Med. 1990, 35:11-14.
221. Sidi A.A., Cameron J.S., Duffy L.M., Lange P.H. Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients. J. Urol. 1986, 135:704-706.
222. Silvestri A., Galetta P., Cerquetani E., Marazzi G., Patrizi R., Fini M., Rosano G.M. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur. Heart J. 2003, 24:1928-1932.
223. Slob W., Pieters M.N. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework. Risk Analysis 1998, 18:787-798.
224. Smaldone M., Sukkarieh T., Reda A., Khan A. Epilepsy and erectile dysfunction: a review. Seizure 2004, 13:453-459.
225. Smith P.J., Talbert R.L. Sexual dysfunction with antihypertensive and antipsychotic agents. Clin. Pharm. 1986, 5:373-384.
226. Soliman G.A., Abla A.M. Effects of antiepileptic drugs carbamazepine and sodium valproate on fertility of male rats. Dtsch. Tierarztl. Wochenschr. 1999, 106:110-113.
227. Sparwasser C., Schmelz H.U., Drescher P., Eckert R., Madsen P.O. Role of intracellular Ca2+ stores in smooth muscle of human penile erectile tissue. Urol. Res. 1998, 26:189-193.
228. Stanczyk F.Z. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Structure-function relationships, potency, and pharmacokinetics of progestogens 1994, 69-89. Raven Press, New York. R.A. Lobo (Ed.).
229. Stanczyk F.Z. Pharmacokinetics of the new progestins and influence of gestodene and desogestrel on ethinylestradiol metabolism. Contraception 1997, 55:273-282.
230. Stanczyk F.Z., Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 1990, 42:67-96.
231. Stanczyk F.Z., Leyden J., Kempers S., et al. The effect of an oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel (EE 20/LNG 100) on ovarian, adrenal, and peripheral androgens. Gynecol Endocrinol. 2000, 14:137. Abstract R.T59.
232. Stanford M.S., Patton J.H. In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol. Biochem Behav. 1993, 45:959-962.
233. Stoker T.E., Goldman J.M., Cooper R.L. Delayed ovulation and pregnancy outcome: effect of environmental toxicants on the neuroendocrine control of the ovary (1). Environ. Toxicol. Pharmacol. 2001, 9:117-129.
234. Stolker A.A., Niesing W., Hogendoorn E.A., Versteegh J.F., Fuchs R., Brinkman U.A. Liquid chromatography with triple-quadrupole or quadrupole-time of flight mass spectrometry for screening and confirmation of residues of pharmaceuticals in water. Anal. Bioanal. Chem. 2004, 378:955-963.
235. Stone S., Khamashta M.A., Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link?. Drug Safety 2002, 25:545-551.
236. Stumpf M., Ternes T.A., Haberer K., Baumann W. Nachweis von naturlichen und synthetischen Ostrogenen in Klaranlagen und Fliessgewassern. Vom Wasser 1996, 87:251-261.
237. Tabak H., Bloomhuff R.N., Bunch R.L. Steroid hormones as water pullutants II. Dev. Ind. Microbiol. 1981, 22:497-519.
238. Tadokoro N., Vollenhoven B., Clark S., Baker G., Kovacs G., Burger H., Healy D. Cumulative pregnancy rates in couples with anovulatory infertility compared with unexplained infertility in an ovulation induction programme. Hum. Reprod. 1997, 12:1939-1944.
239. Tamura K., Abe Y., Kogo H. Phenytoin inhibits both the first ovulation and uterine development in gonadotropin-primed immature rats. Eur. J. Pharmacol. 2000, 398:317-322.
240. Tanaka H., Yakou Y., Takahashi A., Higashitami K., Komori M. Comparison between estrogenicities estimated from DNA recombinant yeast assay and from chemical analyses of endocrine disruptors during sewage treatment. Water Sci. Technol. 2001, 43/2:125-132.
241. Tanyildizi S., Bozkurt T. The effects of lincomycin-spectinomycin and sulfamethoxazole-trimethoprim on hyaluronidase activities and sperm characteristics of rams. J. Vet. Med. Sci. 2003, 65(7):775-880.
242. Tauxe-Wuersch A., De Alencastro L.F., Grandjean D., Tarradellas J. Occurrence of several acidic drugs in sewage treatment plants in Switzerland and risk assessment. Water Res. 2005, 39:1761-1772.
243. Teichmann A.T. Empfängnisverhütung: eine vergleichende Übersicht aller Methoden, Risiken und Indikationen 1996, 23-31. Georg Thieme Verlag, Stuttgart, Germany.
244. Ternes T.A., Stumpf M., Mueller J., Haberer K., Wilken R.D., Servos M. Behavior and occurrence of estrogens in municipal sewage treatment plants - I. Investigations in Germany, Canada and Brazil. Sci. Total Environ. 1999, 225:81-90.
245. Thorneycroft I., Stanczyk F., Bradshaw K., et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999, 60:255-262.
246. Timmermans L. Influence of antibiotics on spermatogenesis. J. Urol. 1974, 112:348-349.
247. Tinajero J.C., Fabbri A., Dufau M.L. Serotonergic inhibition of rat Leydig cell function by propranolol. Endocrinology 1993, 133:257-264.
248. Turkington R.W., Macindoe J.H. Hyperprolactinemia in sarcoidosis. Ann. Intern. Med. 1972, 76:545-549.
249. Uhler M.L., Hsu J.W., Fisher S.G., Zinaman M.J. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil. Steril. 2001, 76:957-961.
250. Vange N Van Der, Blankenstein M.A., Kloosterboer H.J., et al. Effects of several low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990, 41:345-352.
251. Vermeire T., Pieters M., Rennen M., Bos P. Probabilistic assessment factors for human health risk assessment 2001, RIVM report 601516005, TNO report V3489.
252. Vogel D., Gehring D., Tennhardt I., Weltin D., Bilitewski B. Mobility and fate of endocrine disrupting compounds (EDCs) in soil after application of sewage sludge to agricultural land. Proc. 4th Int. Conference ORBIT Ass. on Biol. Process. Organics: Adv. Sustain. Soc 2003, vol. 1:241-250. Perth, Australia, April 30-May 2, 2003. Pullammanappallil, A. McComb, L.F. Diaz, W. Bidlingmaier (Eds.).
253. Vose D. Risk Analysis: A Quantitative Guide 2000, John Wiley &Sons, Chichester.
254. Waghmarae D. Infertility. East Afr. Med. J. 1972, 49:698-702.
255. Wardle P.G., Mitchell J.D., Mclaughlin E.A., Ray B.D., Mcdermott A., Hull M.G. Endometriosis and ovulatory disorder: reduced fertilisation in vitro compared with tubal and unexplained infertility. Lancet 1985, 2:236-239.
256. Warneke L. Phenelzine and sexuality. J. Clin. Psychiatry 1994, 55:216-217.
257. Webb S. Proceedings of International Seminar on Pharmaceuticals in the Environment. Risk assessment for pharmaceuticals 2000, Technological Institute, Brussels.
258. Webb S., Ternes T., Gibert M., Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol. Lett. 2003, 142:157-167.
259. Webster J. Male sexual dysfunction and cimetidine. Br. Med. J. 1979, 1:889.
260. Weiner R.I. Cellular basis of the GnRH pulse generator. Nippon Sanka Fujinka Gakkai Zasshi 1996, 48:573-577.
261. Weiss R.J. Effects of antihypertensive agents on sexual function. Am. Fam. Physician. 1991, 44:2075-2082.
262. Wenzel A., Schäfers C., Vollmer G., Michna H., Diel P. Research Efforts Towards the Development and Validation of a Test Method for the Identification of Endocrine Disrupting Chemicals 2001, Final Report Contract B6-7920/98/000015.
263. White W.B., Andreoli J.W., Cohn R.D. Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants. Clin. Pharmacol. Ther. 1985, 37:387-390.
264. Wiegel S., Aulinger A., Brockmeyer R., Harms H., Loffler J., Reincke H., Schmidt R., Stachel B., Von Tumpling W., Wanke A. Pharmaceuticals in the river Elbe and its tributaries. Chemosphere 2004, 57:107-126.
265. Wilens T.E., Cohen L., Biederman J., Abrams A., Neft D., Faird N., Sinha V. Fluoxetine pharmacokinetics in pediatric patients. J. Clin. Psychopharmacol. 2002, 22:568-575.
266. Wirshing D.A., Pierre J.M., Marder S.R., Saunders C.S., Wirshing W.C. Sexual side effects of novel antipsychotic medications. Schizophr Res. 2002, 56:25-30.
267. Xu S., Zhu B.T., Cai M.X., Conney A.H. Stimulatory effect of clofibrate on the action of estradiol in the mammary gland but not in the uterus of rats. J. Pharmacol. Exp. Ther. 2001, 297:50-56.
268. Yarkoni S., Spitz I.M., Ben David M., Polishuk W.Z. Failure of bromocriptine to suppress prolactin in majeptil-induced hyperprolactinemia. Acta. Eur. Fertil. 1978, 9:185-188.
269. Young A.H., Ashton C.H. Pharmacokinetics of fluoxetine. Trends Pharmacol. Sci. 1996, 17:400.
270. Ying G.-G., Kookana R.S., Ru X.-J. Occurrence and fate of hormone steroids in the environment. Environment Int. 2002, 28:545-551.
271. Zanagnolo V., Dharmarajan A.M., Endo K., Wallach E.E. Effects of acetylsalicylic acid (aspirin) and naproxen sodium (naproxen) on ovulation, prostaglandin, and progesterone production in the rabbit. Fertil. Steril. 1996, 65:1036-1043.
272. Zawar M.P., Deshpande N.M., Gadgil P.A., Mahanta A.A. Histopathological study of endometrium in infertility. Indian J. Pathol. Microbiol. 2003, 46:630-633.
273. Zillioux E.J., Johnson I.C., Kiparissis Y., Metcalfe C.D., Wheat J.V., Ward S.G., Liu H. The sheepshead minnow as anin vivo model for endocrine disruption in marine teleosts: a partial life-cycle test with 17-alpha-ethynylestradiol. Environ. Toxicol. Chem. 2001, 20:1968-1978.
274. Zipper J., Bruzzone M.E., Angelo S., Munoz V., Wheeler R.G. Effect of topically applied adrenergic blockers on fertility. Int. J. Fertil. 1982, 27:242-245.
275. Zuccato E., Castiglioni S., Fanelli R. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J. Hazard. Mater. 2005, 122:205-209.
276. Zuehlke S., Duennbier U., Heberer T. Determination of polar drug residues in sewage and surface water applying liquid chromatography-tandem mass spectrometry. Anal. Chem. 2004, 76:6548-6554.